Why Are Pliant Therapeutics Shares Rallying Today?
February 2, 2024
CNBC
Pliant Therapeutics Inc's (NASDAQ: PLRX ) Phase 2a trial of PLN-74809 in patients with idiopathic pulmonary fibrosis (IPF) met its primary and secondary endpoints .
The data demonstrated that PLN-74809 was well tolerated over a 12-week treatment period and displayed a favorable pharmacokinetic profile.
A pooled analysis of PLN-74809 treated patients showed ... Full story available on Benzinga.com
SweepCast
Simplest Unusual Options Activity Platform for traders. SweepCast can be used for swing or day traders who are looking to get insights on where Smart money is flowing, sign up today.